Aromatase inhibitors: prediction of response and nature of resistance (Q37760220)

22 August 2017

1 reference

title

Aromatase inhibitors: prediction of response and nature of resistance (English)

1 reference

22 August 2017

William R Miller

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

11

1 reference

22 August 2017

page(s)

1873-1887

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Neoadjuvant endocrine therapy for locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Neoadjuvant use of endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Lessons from the use of aromatase inhibitors in the neoadjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Short-term presurgical treatment for all?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Aromatase inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Aromatase inhibitors for breast cancer: lessons from the laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Molecular response to aromatase inhibitor treatment in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Development of the 21-gene assay and its application in clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Fulvestrant and the sequential endocrine cascade for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Controversies in Breast Cancer 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Aromatase inhibitors--gene discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Prevention strategies with aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Biological rationale for endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Estrogen and progesterone receptor isoforms: clinical significance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

Oestrogen receptor: a stable phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.487863

10.1517/14656566.2010.487863

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference